Welcome to our dedicated page for AEON Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AEON Biopharma SEC filings document its ABP-450 biosimilar program, operating and financial results, governance matters, capital structure, and NYSE American listing-status disclosures. Form 8-K reports cover material events such as financial results, Regulation FD presentations, executive appointments and compensatory arrangements, and continued-listing rule notices tied to stockholders’ equity requirements.
Proxy statements record shareholder voting procedures and meeting proposals, including capital-structure approvals tied to Class A common stock, warrants, and senior secured convertible note matters. The filings also identify AEON’s Class A common stock listed on NYSE American and describe disclosure topics common to a development-stage biopharmaceutical issuer.
AEON Biopharma, Inc. (AEON) received a Schedule 13G reporting that Timothy P. Lynch beneficially owns 6,500,000 shares of its Class A common stock. This represents 13.0% of the class, based on 49,882,790 shares outstanding as of August 6, 2026.
Lynch reports sole voting and dispositive power over all 6,500,000 shares, with no shared power. The filing notes additional prefunded warrants for 1,000,000 shares and milestone warrants for 6,000,000 shares are excluded from beneficial ownership because a 4.99% Beneficial Ownership Limitation currently prevents their exercise.
AEON Biopharma, Inc. (AEON) reported that ten percent owner Timothy P. Lynch purchased 1,150,000 shares of Class A Common Stock on August 19, 2026. The weighted average purchase price was $0.2117 per share, with individual trades ranging from $0.1975 to $0.2164. Following this open-market purchase, Lynch directly owns 6,500,000 shares of AEON Class A Common Stock.
AEON Biopharma, Inc. (AEON) disclosed the initial ownership of major shareholder Timothy P. Lynch on a Form 3. Lynch directly holds 5,350,000 shares of Class A Common Stock and derivative securities tied to additional shares. These include pre-funded warrants exercisable at $0.0001 per share for 1,000,000 underlying Class A shares that are exercisable at any time and have no expiration date.
He also holds two series of warrants, each covering 3,000,000 underlying Class A shares, with exercise prices of $0.3221 and $0.3704 per share. Certain warrants expire on the earlier of the second or fifth anniversary of issuance or 45 days after specified AEON FDA-related announcements. A 4.99% beneficial ownership limitation applies, which Lynch may adjust up to 19.99% with at least 61 days’ prior written notice, subject to the warrant terms.
AEON Biopharma, Inc. reported continued operating losses while advancing ABP-450 as a proposed biosimilar to BOTOX. For the six months ended June 30, 2026, the company recorded a net loss of $12.9 million and had an accumulated deficit of $483.8 million. Cash and cash equivalents were $3.4 million and total assets $5.9 million, against total liabilities of $21.3 million, resulting in a stockholders’ deficit of $15.4 million.
Management explicitly states there is substantial doubt about the company’s ability to continue as a going concern, given recurring losses, negative operating cash flow and limited cash. AEON is funding operations through equity and structured financings, including an at-the-market program (2.3 million shares for $2.6 million in the first half of 2026), a $6.0 million PIPE, the exchange of $15.0 million of Daewoong convertible notes into equity, a new $1.5 million senior secured convertible note, and approximately $13.6 million of net proceeds from a July 2026 offering.
AEON progressed its ABP-450 biosimilar program, holding FDA biosimilar meetings, commencing analytical studies, and planning to complete most analytical comparability work in 2026. However, future development, regulatory approval and commercialization remain dependent on securing additional capital under uncertain market and financing conditions.
AEON Biopharma, Inc. reported second quarter 2026 results and a corporate update focused on advancing ABP-450, its proposed biosimilar to BOTOX for therapeutic indications. The company highlighted FDA-regulatory progress, including a Biosimilar Biological Product Development (BPD) Type 2a meeting where the FDA reviewed its analytical similarity strategy under the 351(k) biosimilar pathway and provided feedback that supports AEON’s planned analytical development approach.
AEON completed a $15.3 million underwritten public financing in July 2026, generating approximately $13.6 million in net upfront proceeds and milestone warrants that could provide up to an additional $34.0 million in gross proceeds upon full cash exercise. The company reported cash and cash equivalents of $3.4 million as of June 30, 2026, and expects, including the July proceeds, to fund operations into the first quarter of 2027.
For the quarter ended June 30, 2026, AEON recorded a loss from operations of $5.9 million and a net loss of $1.2 million, with results influenced by non-cash fair value changes in convertible notes and warrant liabilities. Total liabilities were $21.3 million and stockholders’ deficit was $15.4 million as of June 30, 2026. The company also disclosed that it regained full NYSE American continued listing compliance on August 3, 2026.
AEON Biopharma, Inc. reports that it has regained compliance with NYSE American’s continued listing standards. NYSE Regulation confirmed that previously identified deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide have been resolved, so the “.BC” below-compliance indicator is expected to be removed and the company taken off NYSE American’s noncompliant issuers list, while it remains subject to ongoing listing standards.
The company regained compliance following completion of an underwritten public offering closed on July 15, 2026, involving 17,851,599 shares of Class A common stock and pre-funded warrants to purchase 24,837,008 shares, plus an additional 4,696,102 shares sold on July 23, 2026 through a partial over-allotment exercise. AEON received approximately $13.6 million in net proceeds and has the potential to receive up to $34.0 million in additional gross proceeds upon full cash exercise of milestone warrants. AEON believes its stockholders’ equity now exceeds the $4.0 million minimum required under Section 1003(a)(ii), although its June 30, 2026 balance sheet in the upcoming Form 10-Q will still show a stockholders’ deficit and reflect the offering as a subsequent event.
AEON Biopharma, Inc. reports that on July 23, 2026 it issued 4,696,102 additional shares of Class A common stock to the underwriters in its recent public offering, following the representative’s partial exercise of an over-allotment option under an underwriting agreement.
The transaction generated approximately $1.5 million in gross proceeds and approximately $1.4 million in net proceeds after underwriting discounts and commissions. The representative had previously exercised in full the over-allotment portion relating to the two-year and five-year milestone warrants, each covering 6,403,290 shares of common stock or pre-funded warrants in lieu thereof.
AEON Biopharma, Inc. has a new large shareholder group led by Stonepine Capital Management, LLC and related entities, which report beneficial ownership of 6,892,682 shares of Class A Common Stock, representing 9.9% of the outstanding class.
The position consists of 3,000,000 shares of Common Stock and warrants for 6,000,000 shares, all subject to a 9.99% beneficial ownership limitation. The ownership percentage is based on 68,995,818 shares of Common Stock outstanding immediately after an offering, as described in the issuer’s July 15, 2026 prospectus.
Voting and dispositive power over the 6,892,682 shares is reported as shared by Stonepine Capital Management, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico, who file jointly but each disclaims membership in a group and beneficial ownership beyond their pecuniary interest.
AEON Biopharma entered into an underwriting agreement for an underwritten public offering of 42,688,606 shares of Class A common stock (or pre-funded warrants in lieu), with each unit accompanied by one two-year and one five-year milestone warrant. The combined public offering price is $0.3221 per share of common stock (or $0.3220 per pre-funded warrant) and accompanying milestone warrants. The representative also received a 30-day over-allotment option that included additional milestone warrants, which was exercised for 6,403,290 two-year and 6,403,290 five-year milestone warrants.
The offering, which closed on July 15, 2026, is expected to generate approximately $13.75 million in gross proceeds and provided net proceeds of about $12.2 million. If all milestone warrants are exercised in cash, AEON could receive up to an additional $29.6 million. Pre-funded warrants are immediately exercisable at $0.0001 per share with no expiration, subject to 4.99% or 9.99% beneficial ownership caps, adjustable up to 19.99%. Two-year milestone warrants are exercisable at $0.3221 per share and five-year milestone warrants at $0.3704 per share, with expirations tied to fixed anniversaries or specified FDA and clinical milestones for ABP-450. AEON plans to use proceeds for working capital and general corporate purposes, including comparative analytical testing on ABP-450 to support biosimilarity to BOTOX®, and agreed to 90-day issuance and lock-up restrictions and a 180-day ban on variable rate transactions.
AEON Biopharma, Inc. is conducting a public offering of 17,851,599 shares of common stock and pre-funded warrants to purchase 24,837,008 shares, each bundled with two series of milestone warrants. The registration also covers 110,214,222 shares of common stock underlying the pre-funded and milestone warrants.
The deal is priced at $0.3221 per common share with accompanying Milestone Warrants and $0.3220 per pre-funded warrant with accompanying Milestone Warrants, for total gross proceeds of $13.75 million and proceeds before expenses of $12.88 million. AEON expects net proceeds of about $12.2 million, to be used for working capital and comparative analytical testing on ABP-450 as a BOTOX biosimilar, and may receive up to $29.6 million more if all Milestone Warrants are exercised for cash.
Shares outstanding are expected to rise to 68,995,818 assuming full exercise of pre-funded warrants. AEON reports an accumulated deficit of $482.6 million and substantial doubt about its ability to continue as a going concern, and it is working under an NYSE American compliance plan after stockholders’ equity fell below listing thresholds.